Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Vaginal fungi infections is identified by various symptoms such as swelling around the vagina, burning sensation during urination or sex, whitish-gray and clumpy vaginal discharge, and many others. Vaginal yeast infection is also known as candidiasis. A healthy vagina comprises bacteria and few yeast cells, but when the balance of bacteria and yeast changes, the yeast cells can multiply, which further leads to intense itching, swelling, and irritation.

The global vaginal fungi infections treatment market is estimated to be valued at US$ 987.2 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

Figure 1. Global Vaginal Fungi Infections Treatment Market Share (US$ Mn), by Region, 2020

Vaginal Fungi Infections Treatment  | Coherent Market Insights

The increasing product launches is expected to propel growth of the global vaginal fungi infections treatment market

Major players in the market are focused on product launches in the market, which is expected to boost the market growth over the forecast period. For instance, in December 2016, Dr. Reddy’s Laboratories Ltd. launched Nystatin and Triamcinolone Acetonide Cream, USP, approved by the U.S. Food & Drug Administration (U.S. FDA).in the U.S. Nystatin and Triamcinolone Acetonide Cream, USP are the generic equivalent of Nystatin and Triamcinolone Acetonide Cream, USP 100,000 units/g- 0.1% manufactured by Taro Pharmaceuticals USA Inc. and these are used to treat fungal or yeast infections of the skin.

Moreover, increasing inorganics strategies such as business expansion adopted by the market players are expected to propel growth of the global vaginal fungi infections treatment market during the forecast period. For instance, in June 2016, Bausch Health Companies Inc. (previously known as Valeant Pharmaceuticals International, Inc.) announced that its subsidiary Valeant Canada is expanding its manufacturing and export capacity in Canada.

However, alternative therapies for vaginal fungi infections treatment can hinder the market growth. For instance, Pure Essence, a dietary supplement company offers Candex, a mixture of potent enzymes, which break down the substances that make up the cell walls of Candida yeast.

Figure 2. Global Vaginal Fungi Infections Treatment Market Share (%), by Drug Type, 2020

Vaginal Fungi Infections Treatment  | Coherent Market Insights

Increasing opioid abuse in North America is expected to boost the market growth

North America is expected to hold dominant position in the global vaginal fungi infections treatment market, owing to burden of recurrent vulvovaginal candidiasis in this region. For instance, according to The Lancet, an article published in August 2018, reports that in the U.S. there were 3,775 and 3,897 base case prevalence per 100,000 females in the U.S. and Canada respectively.

Moreover, increasing acquisitions by key players in the region is expected to drive the market growth during the forecast period. For instance, in February 2019, Aurobindo Pharma Limited acquired commercial operations and certain supporting infrastructure of Apotex Inc. in five European countries.

request-sample

Vaginal Fungi Infections Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 987.2 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.3% 2027 Value Projection: US$ 1,420.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Fluconazole, Nystatin, Flucytosine, Others.
  • By Route of Administration: Oral, Topical.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.

Growth Drivers:
  • Rising incidence of vaginal fungi infection
  • Product approvals and launches for treatment of vaginal fungi infection
Restraints & Challenges:
  • Increasing adoption of alternative therapies

Global Vaginal Fungi Infections Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global vaginal fungi infections treatment drugs market during the forecast period.

However, the COVID-19 pandemic is also expected to limit growth of the global vaginal fungi infections treatment market during the forecast period. According to the Journal of Clinical Orthopedics and trauma, in May 2020, the coronavirus affects bones and joints of affected patients. As a result, several orthopedic doctors have been deployed for monitoring patients suffering from coronavirus infection. In order to treat such patients, there has been an increase in the manufacture of drugs and research and development.

Key Players

Major players operating in the global vaginal fungi infections treatment market include Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.

A vaginal yeast infection is a fungal infection that causes irritation, discharge, and intense itchiness of the vagina and the vulva — the tissues at the vaginal opening. Vaginal fungi infection is also known as vaginal yeast infection, vulvovaginal candidiasis, candidal vaginitis or vaginal candidiasis, and it the second most common type of vaginal infection in the U.S., according the Centers for Disease Control and Prevention.

Market Dynamics

Rising incidence of vaginal fungi infections are driving vaginal fungi infections treatment market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2018, around 1.4 million outpatient visits occur for vaginal candidiasis every year in the U.S. Moreover, according to an article published in Multidisciplinary Digital Publishing Institute (MDPI) in February 2020, Vulvovaginal candidiasis (VVC) is the most prevalent human candidal infection and nearly 75% women across the globe are affected by it least once in their lifetime. Furthermore, according to the same source, around 8% women across the globe suffer from Recurrent Vulvovaginal Candidiasis (RVVC).

However, alternative therapies for vaginal fungi infections treatment can hinder the market growth. For instance, Nutrablast, a dedicated company in the dietary supplement and personal care offers Tea Tree Suppositories for vaginal fungi infections treatment. The product is natural tea tree oil to provide a balanced vaginal environment.

Key features of the study:

  • This report provides in-depth analysis of the global vaginal fungi infections treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Vaginal Fungi Infections Treatment Market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global Vaginal Fungi Infections Treatment Market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vaginal fungi infections treatment market.

Detailed Segmentation:

  • Global Vaginal Fungi Infections Treatment Market, By Drug Type:
    • Fluconazole
    • Nystatin
    • Flucytosine
    • Others
  • Global Vaginal Fungi Infections Treatment Market, By Route of Administration:
    • Oral
    • Topical
  • Global Vaginal Fungi Infections Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Vaginal Fungi Infections Treatment Market, By Region:
    • North America
      • By Drug Type:
        • Fluconazole
        • Nystatin
        • Flucytosine
        • Others
      • By Route of Administration
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Fluconazole
        • Nystatin
        • Flucytosine
        • Others
      • By Route of Administration
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Fluconazole
        • Nystatin
        • Flucytosine
        • Others
      • By Route of Administration
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Fluconazole
        • Nystatin
        • Flucytosine
        • Others
      • By Route of Administration
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Fluconazole
        • Nystatin
        • Flucytosine
        • Others
      • By Route of Administration
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Fluconazole
        • Nystatin
        • Flucytosine
        • Others
      • By Route of Administration
        • Oral
        • Topical
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bausch Health Companies Inc
    • ANI Pharmaceuticals, Inc.
    • Hikma Pharmaceuticals Plc
    • Lupin Limited
    • Mycovia Pharmaceuticals, Inc.
    • Glenmark Pharmaceuticals Limited
    • Unique Pharmaceuticals
    • PEPTONIC medical AB
    • Aurobindo Pharma Limited
    • Reddy's Laboratories
    • SCYNEXIS, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Vaginal Fungi Infections Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Vaginal Fungi Infections Treatment Products
  5. Global Vaginal Fungi Infections Treatment Market, By Drug Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Fluconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Nystatin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Flucytosine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Vaginal Fungi Infections Treatment Market, By Route of Administration, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Vaginal Fungi Infections Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Vaginal Fungi Infections Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bausch Health Companies Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ANI Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hikma Pharmaceuticals Plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mycovia Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Glenmark Pharmaceuticals Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Unique Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • PEPTONIC medical AB
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aurobindo Pharma Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reddy's Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • SCYNEXIS, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 37 market data tables and 25 figures on "Vaginal Fungi Infections Treatment Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global vaginal fungi infections treatment market size is estimated to be valued at US$ 987.2 million in 2020 and is expected to exhibit a CAGR of 5.3% between 2020 and 2027.
Rising incidence of vaginal fungi infection and product approvals and launches for treatment of vaginal fungi infection are favoring the market growth.
Fluconazole segment is expected to be the leading drug type segment in the global vaginal fungi infections treatment market during the forecast period (2020-2027).
North America vaginal fungi infections treatment market is expected to generate highest revenue share during the forecast period.
Major players operating in the global vaginal fungi infections treatment market include Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner